Table A1.

Reported human clearance and volume of distribution for protein drugs and allometrically scaled human parameter values from animal studies of snake venom toxins.

Compounds	Molecular Weight (kDa)	CL (L·h−1)	V (L)	References
Nesiritide	3.5	38.6a	13.3a	#
Glucagon recombinant	3.8	56.7a	17.5a	#
Abaloparatide	4.0	20.4b	50.0	#
Relaxin	6.0	10.5	17.4	[23]
Neurotoxin (Naja sumatrana)	6.5	2.36†	67.6†c	[11]
Lepirudin	7.0	9.30*	14.5*	#
Cardiotoxin (N. sumatrana)	7.0	2.50†	69.3†c	[11]
Ecallantide	7.1	9.18	26.4	#
Phospholipase A2 (N. sumatrana)	16	1.38†	49.0†c	[11]
Filgrastim	19	2.52a	10.5a	#
rhGH	20	9.14	4.1	[23]
rCD4	50	3.42	4.9	[23]
rt-PA	63	37.2	8.1	[23]
Albumin	67	0.012b	7.7	+, [24]
CD4-IgG	98	0.157	6.3	[23]
Adalimumab	144	0.012	5.4	+
Eculizumab	148	0.022	7.7	#
Infliximab	149	0.016*	5.8*	[25,26,27]

Abbreviations: $CL$ = clearance; $V$ = volume of distribution; rhGH = recombinant human growth hormone; rCD4 = recombinant CD4; rt-PA = recombinant tissue plasma activator; CD4-IgG = CD4-immunoglobin. ^a Human weight is assumed to be 70 kg; ^b $CL$ calculated from half-life and $V$; ^c $V$ at steady state calculated from reported $V$ of central compartment and $V$ of peripheral compartment; * Weighted average; # Information from DrugBank (https://www.drugbank.ca/); + Information from eMC (https://www.medicines.org.uk/emc/) ^† Allometrically scaled $CL$ and $V$ were calculated using the following equation (based on human weight of 70 kg): $C{L}_{\left(human\right)}=C{L}_{\left(animal\right)}\times {\left(\frac{W{T}_{human}}{W{T}_{animal}}\right)}^{0.75}$, and $V_{\left(human\right)}=V_{\left(animal\right)}\times {\left(\frac{W{T}_{human}}{W{T}_{animal}}\right)}^1$.